New mutation in PTEN identified in patient with rare bilateral choroidal ganglioneuroma

Zhaoxin Jiang  
Sun Yat-Sen University

Ting Zhang  
Sun Yat-Sen University

Chonglin Chen  
Sun Yat-Sen University

Limei Sun  
Sun Yat-Sen University

Songshan Li  
Sun Yat-Sen University

Xiaoyan Ding (dingxiaoyan@gzzoc.com)

Research article

Keywords: Choroidal ganglioneuroma, PTEN mutation, Whole exome sequencing

DOI: https://doi.org/10.21203/rs.3.rs-32912/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background

Choroidal ganglioneuroma is an extremely rare tumor, with little known regarding its pathogenesis. The present study aimed to investigate the phenotype and genetic alterations in one sporadic patient with rare bilateral choroidal ganglioneuroma.

Methods

A 6-year-old boy with histological diagnosis of bilateral ganglioneuroma was recruited in this study. Comprehensive ophthalmic examinations were performed in the patient. Genomic DNA was extracted from peripheral blood collected from the patient, the patient's unaffected family members, and from 200 unrelated control subjects from the same population. Whole exome sequencing was carried out and raw reads were aligned to the human genome reference (hg19) using the Burrows Wheeler Aligner. All available family members were subjected to Sanger sequencing for segregation analysis.

Results

Bilateral and extensive retinal detachments were observed in OCT. The diffuse thickening of choroid was identified in B scan and MRI. Genetic analysis revealed the presence of a novel heterozygous PTEN frameshift mutation, c.498delA (p.Thr167LeufsTer16), in exon 6. It was identified in the affected individual, but not in any of the unaffected family members. Genetic analysis showed that there was no mutant in neurofibromatosis-related genes. There were no obvious abnormalities in other organs in comprehensive systemic examinations.

Conclusions

A novel de novo PTEN mutation was identified in a bilateral choroidal ganglioneuroma case. Although PTEN mutation has been considered to induces multiple abnormalities, choroidal ganglioneuroma can be the first manifestation without abnormalities in other organs. Further studies are needed to confirm this new association between choroidal ganglioneuroma and the PTEN mutation.

Background

Choroidal ganglioneuroma is an extremely rare disease, that only 13 cases have been reported in literatures\textsuperscript{1-13}. Ganglioneuroma is benign neurogenic tumor that occurs with an approximate incidence of 1 case per million in the United States for children\textsuperscript{14,15}. It is arising from neural crest\textsuperscript{16}, and considered as a subset of neuroblastomas that histopathologically consist of mature ganglion-like cells.
with scarce immature cells. The underlying mechanism for development of ganglioneuroma is still unclear.

According to the previous reports, blind painful eye was the common feature, and 12 cases have established neurofibromatosis type 1 (NF-1), which lead to the suggestion that choroidal ganglioneuromas could be recognized as a rare manifestation within the clinicopathologic spectrum of NF-1 syndrome. Recently, we confronted with the first case of bilateral choroidal ganglioneuromas, and reported the multimodal imaging features in the early stage.

Aiming to unravel the pathogenesis of this rare disease, whole exome sequencing was carried out in this patient. As a phosphatase and tensin homolog (PTEN) mutation was identified, comprehensive systemic examinations were performed to screen the presence of concomitant abnormalities.

**Methods**

**Study participants**

This study was carried out according to the guidelines approved by the Ethics Committee of Zhongshan Ophthalmic Center (ZOC), Sun Yat-sen University and in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects.

A 6-year-old boy complaining of gradual vision loss bilaterally for 2 years presented in Pediatric Ophthalmology Department, ZOC. Comprehensive ophthalmic examinations were performed including visual acuity, intraocular pressure (IOP), slit lamp microscopy, fundus photography (Heidelberg Engineering, Inc., Heidelberg, Germany), optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA, USA), ultrasound B scan (Aitomu Machinery Co. Ltd, Shanghai, China), and magnetic resonance imaging (MRI; General Electric, Milwaukee, WI). As choroidal ganglioneuroma was diagnosed based on previous choroidal biopsy, extensive examinations were performed to screen any systemic involvements. Whole exome sequencing was carried out to unravel the genetic pathogenesis of this rare disease.

**DNA sample collection**

Blood samples were collected from this proband, his unaffected family members, and 200 unrelated control subjects from the same population. Genomic DNA was extracted using the TIANamp Blood DNA Kit (Tiangen Biotech, Beijing, China) as instructed by the manufacturer. The quantity and quality of DNA was verified by NanoDrop (2000c Model, Thermo Fisher, US).

**Library preparation and targeted sequencing**

According to the manufacturer’s protocol, Illumina paired-end libraries were prepared using Kapa LTP library prep kit (Roche, Basel, Switzerland). Briefly, genomic DNA was sheared into fragments of approximately 300–500 bp in length. The DNA fragments were end-repaired and an extra ‘adenine’ base
was added to the 3' end. Illumina adapters were ligated to the ends of the DNA fragments and four cycles of PCR amplification were applied to each sample after ligation. The DNA libraries were quantified by the Qubit 3.0. Pre-capture libraries were pooled together for one capture reaction. Agilent SSELXT Human All Exon V6 was used for whole exome sequencing (Agilent, Santa Clara, CA, USA). The enriched DNA library was sequenced on Illumina Xten Analyzers for 150 cycles per read to generate paired-end reads following the manufacturer's standard sequencing protocols.

**Bioinformatics analysis of sequencing results**

Raw reads were aligned to the human genome reference (hg19) using the Burrows Wheeler Aligner. Single-nucleotide variants (SNVs) and insertions and deletions (InDels) were called by GATK4.0 HC. The frequency of all SNVs and InDels were annotated using the ExAC, gnomAD, HGVD, CHARGE, 1000 Genome, UK10K databases, and the internal database of Clinbytes Inc. to filter the common variants, with an allele frequency cutoff of 0.5% and 0.1% for recessive and dominant variants, respectively.

**Genetic validation**

After any pathologic variants were confirmed in the proband, samples from all available family members were subjected to Sanger sequencing for segregation analysis. PCR primer sets were designed via Primer3 and products were sequenced on an ABI 3700XL Genetic Analyzer. Primers used for amplification of PTEN are forward 5'-GGCTACGACCCAGTTACCATAG-3' and reverse 5'-TGGGACAGGTTCTTCCATCATC-3'.

**Results**

**Ocular findings**

In initial examination in 2 years ago, the best corrected visual acuity was 20/50 in the right eye and 20/32 in the left. In recent visit, it was hand motion/10 cm and 20/200, respectively. The IOP had fluctuated around the normal range in the past, but 40 mmHg IOP was observed in recent visit, and was controlled well with brinzolamide-timolol eyedrops.

Bilateral and extensive retinal detachments were observed in OCT. The diffuse thickening of choroid was identified via B scan and MRI (Figure 2). Choroidal tumor was highly suspected, and following choroid biopsy demonstrated the histological diagnosis of choroidal ganglioneuroma. More details on the multimodal images can be found in our previous report²⁰.

**Mutation screening**

Genetic analysis documented the presence of a heterozygous PTEN frameshift mutation, c.498delA (p.Thr167LeufsTer16) in exon 6 (NM_000314). It was identified in the affected individual, but not in any of the unaffected family members; therefore, this was considered a de novo mutation. The identified mutation had not previously been reported, and was not observed in a large population cohort (Figure 3).
The c.498delA variant causes a frameshift starting with codon Threonine167, changing this amino acid to a Leucine residue, and creates a premature Stop codon at position 16 of the new reading frame, denoted p.Thr167LeufsTer16. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.

As most reported cases showed a medical history of NF-1, genetic changes in neurofibromatosis-related genes were evaluated. Genetic analysis showed that there was no mutant in NF1- or NF2-related genes.

Systemic workup

According to histological finding of ganglioneuromas and the mutation in PTEN, it is crucial to rule out the presence of ganglioneuromas, or PTEN related abnormalities in other tissues. Comprehensive systemic examinations were performed in the case, including general physical examination, ultrasound scan of the thyroid gland, liver and kidney, CT scan of the mediastinum and retroperitoneum, and no obvious abnormalities were detected.

Discussion

According to the reported studies (Table 1), most cases of choroidal ganglioneuroma share the same features. First, most cases of uveal ganglioneuroma co-occurred with NF-1, leading to the diagnosis as NF-1 with orbit-facial involvement\textsuperscript{19}. Second, ganglioneuroma leads blind and painful eye unilaterally, and end up with evisceration/enucleation in all cases. Third, ganglioneuroma were diagnosed unexpected only after subsequent histopathological examination. Genetic examination was performed in only one case diagnosed as Cowden syndrome and revealed a PTEN mutation.

In this case, retinal detachments were the major early manifestations, and choroidal tumor was suspected when choroidal thickness increases. There were no clinical features that supporting NF-1 throughout extensive examinations. Choroidal biopsy was performed and revealed the diagnosis of ganglioneuroma\textsuperscript{20}. Interestingly, this is the first case of bilateral choroidal ganglioneuroma. Thus, whole exome sequencing was performed and identified a de novo PTEN mutation. PTEN is a tumor suppressor gene that classically dampens the PI3K/AKT/mTOR growth-promoting signaling cascade\textsuperscript{21}. Loss of PTEN function results in increased cell proliferation, survival, and tumorigenesis\textsuperscript{22, 23}, manifesting with diverse human pathologies, and leading to the use of the umbrella term, PTEN hamartoma tumor syndrome (PHTS)\textsuperscript{24, 25}. Thus, based on histologic features, this case is diagnosed as choroidal ganglioneuroma. On the other side, based on genetic finding, this case is diagnosed as PHTS manifesting with choroidal ganglioneuroma.

The most common features of PHTS patients are macrocephaly, gastrointestinal polyps with various histological patterns, and dermatological lesions including trichilemmoma and oral papillomatosis, which are each, found in around 90% of the PTEN mutation carriers\textsuperscript{26, 27}. For instances, De Paris et al identified a PTEN mutation in a case of Cowden syndrome, who manifested with features including unilateral uveal
ganglioneuroma, macrocephaly, developmental delay, arteriovenous malformation, and a strong family history of early-onset uterine cancer. However, in current case, systemic examinations fail to identify any diagnostic criteria of PHTS. Thus, this is the first case of a patient with heterozygous PTEN mutation, who manifested as choroidal ganglioneuroma without any obvious abnormalities in other organs.

Although the pathogenic gene has been identified, the mechanisms are still unknown yet that why it causes bilateral choroidal ganglioneuroma, without any obvious changes throughout the whole body. This may be attributed to the young age of this patient. Studies have reported features with respect to age of onset in PTEN mutation carriers. For instances, the onset age of breast cancer of PHTS is believed to be around age 38–50 years, and average age of diagnosis are in the 40s for PHTS related cancers in thyroid, endometrial and colon\textsuperscript{28-30}. Thus, genetic study is important the patients, as PTEN mutation has been considered to increase risks for multiple common cancers. Lifetime cancer risk estimates and close follow-up are highly required for the young boy in the present case.

One limitation of the present study is the limited case number. Choroidal ganglioneuroma is an extremely rare disease and most reported cases are not diagnosed until evisceration/enucleation. Therefore, it might be very difficult to recruit enough cases for a case-series study. To this point, biopsy and genetic testing are critical for the early and accurate diagnosis of choroidal ganglioneuroma.

**Conclusion**

A novel de novo PTEN mutation was identified in a bilateral choroidal ganglioneuroma case. Although PTEN mutation has been considered to induces multiple abnormalities, choroidal ganglioneuroma can be the first clinic manifestation without abnormalities in other organs. Further studies are needed to confirm this new association between choroidal ganglioneuroma and the PTEN mutation.

**Availability Of Data And Materials**

The datasets used for the current study are available from the corresponding author on reasonable request.

**Abbreviations**

IOP
Intraocular pressure
OCT
Optical coherence tomography
NF-1
Neurofibromatosis type 1
PTEN
Phosphatase and tensin homolog
References

1. Wolter JR, Bryson JM, McKee TP. Ganglioneuromelanocytosis of the Choroid with Bilateral Juvenile Glaucoma. *Arch Ophthamol* 1965;74:353-356.

2. Woog JJ, Albert DM, Craft J, Silberman N, Horns D. Choroidal ganglioneuroma in neurofibromatosis. *Graefes Arch Clin Exp Ophthamol* 1983;220:25-31.

3. Brownstein S, Little JM. Ocular neurofibromatosis. *Ophthalmology* 1983;90:1595-1599.

4. Shome D, Vemuganti GK, Honavar SG. Choroidal ganglioneuroma in a patient with neurofibromatosis type 1: a case report. *Eye (Lond)* 2006;20:1450-1451.

5. Ishijima K, Kase S, Noda M, Ishida S. Intraocular neovascularization associated with choroidal ganglioneuroma in neurofibromatosis type 1. *Eur J Ophthamol* 2011;21:837-840.

6. Lad EM, Karamchandani JR, Alcorn DM, Moshfeghi DM, Egbert PR. Retinal glioneuronal hamartoma in neurofibromatosis type 1. *Arch Ophthalmol* 2012;130:1335-1337.

7. Yazici B, Ozgun G, Adim SB. Choroidal ganglioneuroma in a patient with orbitopalpebral neurofibromatosis. *Ophthalmic Plast Reconstr Surg* 2014;30:e140-142.

8. Goyal S, Park A, Zeglam A, Brown H, Pemberton JD. Choroidal Ganglioneuroma and Orbital Plexiform Neurofibroma Presenting as Buphthalmos in an Infant With Neurofibromatosis Type 1. *Ophthalmic Plast Reconstr Surg* 2016;32:e87-89.

9. Chang I, Juric-Sekhar G, Marshall D, Zhang J. An Incidental Finding of Choroidal Ganglioneuronal Hamartoma in a Patient With Neurofibromatosis Type 1. *Ophthalmic Plast Reconstr Surg* 2017;33:S40-S42.

10. Mbagwu M, Rahmani B, Srivastava A, Burrowes D, Bryar PJ. Unsuspected Ganglioneuroma of the Choroid Diagnosed after Enucleation. *Ocul Oncol Pathol* 2015;2:48-50.

11. Abdulkader MM, Dalesandro MF, Mendenhall SK, Shah MV, Bonnin JM. Ciliochoroidal ganglioneuroma in neurofibromatosis type 1: Report of a case and review of the literature. *Neuropathology* 2016;36:464-469.

12. DeParis SW, Bloomer M, Han Y, et al. Uveal Ganglioneuroma due to Germline PTEN Mutation (Cowden Syndrome) Presenting as Unilateral Infantile Glaucoma. *Ocul Oncol Pathol* 2017;3:122-128.

13. Gilani A, Treece A. Choroidal Ganglioneuronal Hamartoma in Neurofibromatosis Type-1. *J Pediatr Ophthamol Strabismus* 2018;55:412.

14. De Bernardi B, Gambini C, Haupt R, et al. Retrospective study of childhood ganglioneuroma. *J Clin Oncol* 2008;26:1710-1716.

15. Geoerger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F. Metabolic activity and clinical features of primary ganglioneuromas. *Cancer* 2001;91:1905-1913.
16. Dai X, Zhang R, Li Y, Wu G. Multiple ganglioneuromas: a report of a case and review of the ganglioneuromas. *Clin Neuropathol* 2009;28:193-196.

17. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglieneuroma: radiologic-pathologic correlation. *Radiographics* 2002;22:911-934.

18. Wu W, Xu WJ, Liu JB, Sun J, Huang YM, Lv ZB. Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma. *Math Biosci Eng* 2019;16:7217-7229.

19. Ozgun G, Adim SB, Ugras N, Yazici B. Co-occurrence of choroidal pigmented ganglioneuroma and plexiform neurofibroma in a patient with neurofibromatosis 1. *Kaohsiung J Med Sci* 2014;30:215-216.

20. Jiang Z, Zhang T, Xiu X, Liang D, Zhong Y, Chan C, Ding X. Multimodal Imaging Features of Bilateral Choroidal Ganglioneuroma. *J Ophthalmol* 2020;Accepted.

21. Yehia L, Keel E, Eng C. The Clinical Spectrum of PTEN Mutations. *Annu Rev Med* 2019.

22. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. *Annu Rev Pathol* 2009;4:127-150.

23. Wang Y, Liu Y, Du Y, Yin W, Lu J. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. *Curr Med Res Opin* 2013;29:633-642.

24. Mester J, Charis E. PTEN hamartoma tumor syndrome. *Handb Clin Neurol* 2015;132:129-137.

25. Ngeow J, Eng C. Germline PTEN Mutation Analysis for PTEN Hamartoma Tumor Syndrome. *Methods Mol Biol* 2016;1388:63-73.

26. Reddy KV, Anusha A, Maloth KN, Sunitha K, Thakur M. Mucocutaneous manifestations of Cowden's syndrome. *Indian Dermatol Online J* 2016;7:512-515.

27. Pilarski R. PTEN Hamartoma Tumor Syndrome: A Clinical Overview. *Cancers (Basel)* 2019;11.

28. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-407.

29. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet* 2013;50:255-263.

30. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. *Fam Cancer* 2014;13:57-63.

### Declarations

#### Acknowledgements

We would like to thank Dr. Chi-chao Chan from National Eye Institute, USA, for her professional opinion in the pathological diagnosis, Prof. Xiaoyan Peng from Beijing Tongren Hospital, China, for her great help in imaging analysis.

#### Funding
This study was supported in part by grants from the Fundamental Research Funds of State Key Laboratory of Ophthalmology, research funds of Sun Yat-sen University (15ykjc22d; Guangzhou, Guangdong, China), and Science and Technology Program Guangzhou, China (201803010031; Guangzhou, Guangdong, China). The sponsors and funding organizations had no role in the design or conduct of this research.

**Author information**

Zhaoxin Jiang and Ting Zhang contribute equally to this work.

**Affiliations**

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

Zhaoxin Jiang, Ting Zhang, Chonglin Chen, Limei Sun, Songshan Li & Xiaoyan Ding

**Contributions**

DXY conceived and designed the study. JZX, ZT, CCL and LSS participated in data collection, laboratory analysis and interpretation. JZX and SLM analyzed the data and wrote the first draft of the manuscript. DXY and CCC critically reviewed the manuscript. All authors approved the submitted version.

**Ethics approval and consent to participate**

All procedures adhered to the tenets of the Declaration of Helsinki, and local approval was received from the Investigational Review Board of Zhongshan Ophthalmic Center, Sun Yat-sen University.

Written informed consent for participation in the study was obtained where participants are children (under 16 years old) from their parent or guardian

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Table**

**Table 1. Clinical profiles of choroidal ganglioneuroma cases in literature.**
| Case | Sex      | Age (Years) | Eye  | Clinical presentation | NF-1 | Treatment          |
|------|----------|-------------|------|-----------------------|------|--------------------|
| 1    | Wolter   | Femal       | 42   | Left                  | Yes  | Enucleation        |
|      |          |             |      | Cataract, glaucoma, buphthalmos |      |                    |
| 2    | Woog et al | Femal       | 21   | Left                  | Yes  | Enucleation        |
|      |          |             |      | Cataract, retinal detachment, buphthalmos |      |                    |
| 3    | Browstein et al | Femal       | <1   | Left                  | Yes  | Enucleation        |
|      |          |             |      | Congenital glaucoma, buphthalmos, plexiform neurofibroma |      |                    |
| 4    | Shome et al | Male        | 11   | Left                  | Yes  | Evisceration       |
|      |          |             |      | Glaucoma, buphthalmos, plexiform neurofibroma, sphenoid wing dysplasia |      |                    |
| 5    | Ishijima et al | Male        | 7    | Left                  | Yes  | Enucleation        |
|      |          |             |      | Cataract, retinal detachment, buphthalmos |      |                    |
| 6    | Lad et al | Femal       | <1   | Right                 | Yes  | Enucleation        |
|      |          |             |      | Cataract, buphthalmos, sphenoid wing dysplasia |      |                    |
| 7    | Yazici et al | Femal       | 17   | Left                  | Yes  | Evisceration       |
|      |          |             |      | Cataract, glaucoma, buphthalmos plexiform neurofibroma |      |                    |
| 8    | Goyal et al | Femal       | <1   | Right                 | Yes  | Exenteration via   |
|      |          |             |      | Buphthalmos, |      |                    |
| No. | Authors            | Gender | Age | Side | Main Diagnoses                                      | Treatment                  |
|-----|--------------------|--------|-----|------|----------------------------------------------------|----------------------------|
| 9   | Chang et al        | Male   | 42  | Right| Cataract, optic nerve, glioma, neurofibroma,        | Enucleation                |
|     |                    |        |     |      | craniotomy access.                                 |                            |
| 10  | Mbagwu et al       | Female | 5   | Right| Proptosis, glaucoma, sphenoid wing dysplasia       | Enucleation                |
| 11  | Abdulkader et al   | M      | 50  | Right| Cataract, glaucoma, buphthalmos, plexiform neurofibroma, frontoethmoidal encephalocele | Orbital exenteration       |
| 12  | DeParis et al      | Female | 5   | Right| Glaucoma, retinal detachment, macrocephaly, developmetal delay | Enucleation                |
| 13  | Gilani et al       | Male   | 7   | Not mentioned | Invading plexiform neurofibroma, choroidal layer expanding | Enucleation                |
| 14  | Present case       | Male   | 6   | Bilateral | Retinal detachment and diffuse choroidal thickening | IOP lowering medicine     |
Figures

Figure 1

Pedigree of the family of the patient identified with choroidal ganglioneuroma. Squares represent males, circles represent females, arrows indicate proband, and black symbol identifies the clinically affected individual.
Figure 2

Images of comprehensive ophthalmic examinations. (A) The bilateral pupils were irregular and unable to dilate. (B) Funduscopy showed vasculitis and exudation bilaterally. (C) Bilateral retinal detachment was observed in optical coherence tomography. Choroidal vasculature was dramatically absent. (D) A dome-shaped mass bulging from choroid to retina was observed in B scan. (E) The diffuse thickening of bilateral choroids was verified by magnetic resonance imaging.
Figure 3

DNA sequence of a region of the PTEN gene in the patient and unaffected individuals. A heterozygous PTEN frameshift mutation c.498delA (p.Thr167LeufsTer16) in exon 6 (NM_000314) was identified in the affected individual, but not in the unaffected family members or unrelated control subjects.